CClinicalTrials.gg
CompletedNCT07587762Updated Aug 7, 2026

Predicting the Clinical Advantages of Speaking Valves Through Wearable Devices

An interventional study of Tracheostomy patients who are able to tolerate wearing a speaking valve for 30 minutes in Physiological Parameter, Wearable Devices and Tracheostomy, sponsored by Bin Zhang. Completed at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Bin Zhang · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The population included in this study consists of tracheostomy patients admitted to the pulmonary department of Beijing Rehabilitation Hospital, undergoing decannulation rehabilitation treatment. Once patient conditions stabilized, they were all transitioned to the decannulation process established by our department in 2018, which utilizes a speaking valve instead of capping.The initial duration for the patient to wear the speaking valve is 30 minutes.The monitoring period for wearable devices is from 1 hour before the initial use of the speaking valve to 1 hour after its removal.Monitored for a total of 2 hours and 30 minutes.Explore the clinical benefits of the speaking valve by comparing the changes in patients' physiological parameters and clinical index metrics before and after using the speaking valve.

Criteria for the successful use of the speaking valve for 30 minutes:

  1. Breathing is steady at rest: no apparent dyspnea, chest tightness, or orthopnea, etc.
  2. Heart rate, blood pressure, and SpO₂ are all stable overall.SpO₂ reduction from baseline \< 5%.
  3. No frequent need for emergency sputum suction or indications of sputum blockage while wearing it.
02

Conditions studied

  • Physiological Parameter
  • Wearable Devices
  • Tracheostomy

Keywords

  • speaking valve
  • Wearable Devices
  • tracheostomy
  • Physiological Parameter
03

In context

Lead sponsor

Bin Zhang is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 90 years≥Age≥18 years;
  • Tracheotomy post-operation>48 hours;
  • Weaned off mechanical ventilation;
  • Clinically stable condition;
  • Tolerable for cuff deflation;
  • Able to tolerate wearing a speaking valve continuously for 30 minutes;
  • Signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients with abnormal skin conditions preventing continuous wearing of monitoring devices;
  • Inability to tolerate wearing a speaking valve continuously for 30 minutes;
  • Interruption of physiological monitoring data;
  • Poor quality of physiological monitoring data;
  • Recently underwent neck/upper airway surgery (≤48 hours, to avoid airflow impact on the upper airway);
  • Severe consciousness disturbance/delirium (RASS score≤-3 or ≥ +2), extreme anxiety/uncooperativeness;
  • Total laryngectomy or laryngotracheal separation;
  • Age \<18 years or >90 years;
  • Malignant tumor with an expected survival time ≤6 months;
  • The patient or legal representative is unable to sign the informed consent form.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Successfully wore the speaking valve for the first time for 30 minutes.

    Inclusion Criteria: 1. Breathing is steady at rest: no apparent dyspnea, chest tightness, or orthopnea, etc. 2. Heart rate, blood pressure, and SpO₂ are all stable overall.SpO₂ reduction from baseline \< 5%. 3. No frequent need for emergency sputum suction or indications of sputum blockage while wearing it.

    Other: Tracheostomy patients who are able to tolerate wearing a speaking valve for 30 minutes

Interventions

  • OtherTracheostomy patients who are able to tolerate wearing a speaking valve for 30 minutes

    Once patient conditions stabilized, they were all transitioned to the decannulation process established by our department in 2018, which utilizes a speaking valve instead of capping.The initial duration for the patient to wear the speaking valve is 30 minutes.If the patient can tolerate wearing the speaking valve for 30 minutes, they fulfill the inclusion criteria.The monitoring period for wearable devices is from 1 hour before the initial use of the speaking valve to 1 hour after its removal.Monitored for a total of 2 hours and 30 minutes. Physiological parameters recorded prior to wearing the speaking valve served as the baseline.Compare the physiological parameters while wearing the speaking valve and after its removal to investigate the clinical benefits that the speaking valve can provide.To promote the application of speaking valves in future clinical work more effectively

06

What researchers measure

Primary outcomes

  1. degree of change in oxygen saturation(%)

    Previous studies have been concerned that speaking valve placement increases upper airway resistance, thereby inducing dyspnea and hypoxemia in patients. Therefore, we used continuous wearable physiological monitoring devices to observe changes in oxygen saturation before, during, and after the training.

    Time frame: Using wearable biosensors, high-resolution physiological data were continuously collected during three phases: baseline (30 minutes), speaking valve placement period (30 minutes), and recovery period (30 minutes after speaking valve removal).

  2. Temporal rate of change of asymmetric cardiovascular responses and delayed autonomic recovery(percentage change from baseline)

    The rate of change (percentage per minute) in asymmetric cardiovascular responses (e.g., heart rate variability indices) and delayed autonomic recovery will be calculated. Physiological data (heart rate, HRV metrics) are continuously collected before, during, and after speaking valve placement. The primary reported value is the slope of change over time, expressed as a percentage relative to baseline, aggregated across all participants using mixed-effects modeling to produce a single mean rate of change

    Time frame: 30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session

  3. Rate of respiratory phase variation during training(percentage change in phase duration)

    The rate of change in respiratory phase variation (e.g., changes in inspiratory/expiratory time proportion) during speaking valve training. Respiratory parameters are continuously recorded. The outcome is the calculated rate of change (percentage per minute) from baseline to the active training period and to the recovery period. A single aggregated value (mean slope) will be derived from all participants using linear mixed models.

    Time frame: 30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session

07

Study locations

1 site
  • Beijing Rehabilitation Hospital, Capital Medical University
    Beijing, Beijing Municipality 100144, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07587762
Lead sponsor
Bin Zhang
Collaborators
Capital Medical University, Chinese PLA General Hospital
Responsible party
Bin Zhang (Principal Investigator, Capital Medical University) — Sponsor-investigator
First posted
May 14, 2026
Start date
Apr 16, 2026
Primary completion
Jul 30, 2026
Completion
Jul 31, 2026
Last update
Aug 7, 2026

Study contacts

Hongying Jiang
study chair · Beijing Rehabilitation Hospital of Capital Medical University, Beijing, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion